Literature DB >> 16000348

Making antimalarial agents available in Africa.

Kenneth J Arrow1, Hellen Gelband, Dean T Jamison.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16000348     DOI： 10.1056/NEJMp058168

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Parenteral artesunate for treatment of severe malaria.

Authors:  Mary E Wilson
Journal:  Curr Infect Dis Rep       Date:  2006-01       Impact factor: 3.725

2.  Syndromic diagnosis of malaria in rural Sierra Leone and proposed additions to the national integrated management of childhood illness guidelines for fever.

Authors:  Obinna N Nnedu; Bryan Rimel; Carey Terry; Heidi Jalloh-Vos; Brima Baryon; Daniel G Bausch
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

3.  Financial implications of refugee malaria: the impact of pre-departure presumptive treatment with anti-malarial drugs.

Authors:  Stefan Collinet-Adler; William M Stauffer; David R Boulware; Kevin L Larsen; Tyson B Rogers; David N Williams
Journal:  Am J Trop Med Hyg       Date:  2007-09       Impact factor: 2.345

4.  Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.

Authors:  Wirichada Pongtavornpinyo; Shunmay Yeung; Ian M Hastings; Arjen M Dondorp; Nicholas P J Day; Nicholas J White
Journal:  Malar J       Date:  2008-11-02       Impact factor: 2.979

5.  Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.

Authors:  Adoke Yeka; Grant Dorsey; Moses R Kamya; Ambrose Talisuna; Myers Lugemwa; John Bosco Rwakimari; Sarah G Staedke; Philip J Rosenthal; Fred Wabwire-Mangen; Hasifa Bukirwa
Journal:  PLoS One       Date:  2008-06-11       Impact factor: 3.240

6.  Antimalarial therapy selection for quinolone resistance among Escherichia coli in the absence of quinolone exposure, in tropical South America.

Authors:  Ross J Davidson; Ian Davis; Barbara M Willey; Keyro Rizg; Shelly Bolotin; Vanessa Porter; Jane Polsky; Nick Daneman; Allison McGeer; Paul Yang; Dennis Scolnik; Roy Rowsell; Olga Imas; Michael S Silverman
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

7.  Cost of increasing access to artemisinin combination therapy: the Cambodian experience.

Authors:  Shunmay Yeung; Wim Van Damme; Duong Socheat; Nicholas J White; Anne Mills
Journal:  Malar J       Date:  2008-05-20       Impact factor: 2.979
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.